UNICREDIT BANK/CALL/ASTRAZENECA/12000/0.1/18.06.25 | Market Closed - Börse Stuttgart 12:19:26 23/05/2024 am IST | ||
| 1.83 EUR | +6.40% |
|
| Current month | +5.52% | ||
| 1 month | +73.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 1.83 | +6.40% |
| 21/24/21 | 1.72 | +5.52% |
| 20/24/20 | 1.63 | -1.81% |
| 17/24/17 | 1.66 | -1.78% |
| 16/24/16 | 1.69 | -1.17% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 12:19 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD1H8A |
| ISIN | DE000HD1H8A8 |
| Date issued | 28/12/2023 |
| Strike | 12,000 p |
| Maturity | 18/06/2025 (392 Days) |
| Parity | 10 : 1 |
| Emission price | 0.86 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.92 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.14 € |
| Spread % | 7.04% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.3
USD
Average target price
169.4
USD
Spread / Average Target
+7.67%
- Stock Market
- Warrants
- Warrant
